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Polycyclic aromatic hydrocarbons are compounds which are formed during the incomplete
combustionof organic compounds such as coal, oil, gas, wood, refuse and tobacco. The group
comprises more than 100 different compounds, although this report will only cover 23
compounds, namely
naphthalene
fluoranthene
chyrsene
anthracene
dibenz(a,h)anthracene
dibenz(a,c)anthracene
benz(a)anthracene
phenanthrene
1-methylphenanthrene
benzo(b)fluoranthene
benzo(j)fluoranthene
benzo(k)fluoranthene
pyrene
benzo(a)pyrene
benzo(e)pyrene
cyclopenta(c,d)pyrene
indeno(1,2,3-c,d)pyrene
perylene
benzo(g,h,i)perylene
fluorene
acenaphthylene
acenaphthene
coronene
Table 1 lists the empirical formulae, CAS numbers and PAH grouping of these compounds.
The physical-chemical properties which may be of relevance to the behaviour of these
compounds in the atmosphere are listed in Table 2.
The relationship between cancer and exposure to coal tar, soot, coke oven emisions and
cigarette smoke has been well documented. Coal soots, coal tar, pitch and coal tar fumes (all
of which contain benz(a)anthracene, benzo(b)fluoranthene, benzo(j)fluoranthene,
benzo(k)fluoranthene and benzo(a)pyrene) have been classified by the International Agency
for Research on Cancer (IARC) as group 1, "carcinogenic to humans". Cancer is the most
significant endpoint of PAH toxicity. US Department of Health & Human Services (1993b)
reportedan increased incidence of cancers of the lung, skin, gastro-intestinal tract and bladder
following exposure to PAHs. Chronic exposure increasesthe likelihood of cancer initiation, as
well as the potential for metabolismof a PAH procarcinogento a carcinogen (Holbrook, 1990).
Manyof the studies on both laboratoryanimalsand occupationallyexposed humans have been
based on PAH mixtures. The relationship between individual PAH compounds and
carcinogenicity is not a straightforwardone. Carcinogenicity increases with the number of rings
in the compound, however some 6 ring PAH compounds such as benzo(g,h,i)perylene are
classified as non-carcinogenic. Carcinogenicity is also determined by the shape of the
molecule; benz(a)pyrene is classified as strongly carcinogenic, whereas its isomer
benz(e)pyrene is classified as non-carcinogenic. PAH compounds with a "bay region", the
area between three aromatic rings arranged in a crescent formation, are known to be
carcinogens. However some "bay region" compounds such as benzo(e)pyrene and
benzo(g,h,i)perylene are classified as non-carcinogenic
This report will detail carcinogenicity studies of exposure of laboratory mammals to individual
PAH compounds via the inhalation route. Where such information exists, the relative potency
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of each.compound with reference to the carcinogenisity of benz(a)pyrene will be calculated.
The relative potency can then be used to set a regulatory assessment level (RAL) for either
individual PAH compounds, or as total PAH.
The carcinogenicity of PAHs has been reported in the following reviews, Harvey, (1991); US
Department of Health & Human Services, (1993b); US Department of Health & Human
Services, (1990f).
Comparison of separate carcinogenicity studies is generally more difficult than the methods
used to compare acute toxicity studies which have standard end-points such as LC50or
NOELs. Different researchers measure different carcinogenicity endpoints, e.g. number of
tumour bearing animals, number of tumours per affected animal, percentage response rate,
incidenceof a specific tumour type, lowest dose causing tumour development, or highest dose
which did not induce tumour development. Comparison can only be made between different
PAHcompoundswhen they were tested using identicalmethodologies, which normally consists
of a single study with separate exposure groups for each individual compound.
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Table:1 Identity of PAH compounds
Name EmpiricalFormula CAS Na No.
Rings
PAH group
naphthalene C10 H8 91-20-3 2


fluoranthene C16 H10 206-44-0 4 nonalterant polyarene
chrysene" C18 H12 218-01-9 4 alterant tetracyclic polyarene
anthracene C14 H10 120-12-7


dibenz(a,h)anthracene C22 H14 53-70-3 5 alternant pentacyclic
polyarene
dibenz(a,c)anthracene C22 H14 215-58-7 5 alternant pentacyclic
polyarene
benz(a)anthracene C18•H12 56-55-3 5 alternant tetracyclic
polyarene
phenanthrene C14 H10 85-01-8 3


1-methylphenanthrene C15 H12 832-69-9 3


benzo(b)fluoranthene C20 H12 205-99-2 5 nonalterant polyarene
benzo(j)fluoranthene C20 H12 205-82-3 5 nonalterant polyarene
benzo(k)fluoranthene C20 H12 207-08-9 5 nonalterant polyarene
pyrene C16 H10 129-00-00 4 alternant tetracyclic
polyarenes
benzo(a)Pyrene C20 H12 50-32-8 5 alternant pentacyclic
polyarene
benzo(e)pyrene C20 H12 192-97-2 5 alternant pentacyclic
polyarene
cyclopenta(c,d)pyrene C18 H10 27208-37-3 5 nonalterant polyarene
indeno(1,2,3-cd)pyrene C22 H12 193-39-5 6 nonalterant polyarene
perylene C20 H12 198-55-0 5 alternant pentacyclic
polyarenes
benzo(ghOperylene C22 H12 191-24-2 6 alternant hexacyclic
polyarenes
fluorene C13 H10 86-73-7 3 nonalterant polyarenes
acenaphthylene C12 H8 208-96-8 3


acenaphtene C12 H10 83-32-9


coronene C24 H12 191-07-1


3 rings vapour phase
4 rings vapour or particulate phase
5 rings particulate phase
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Table 2: Physical-chemical properties of PAH compounds
Name Molecularweight
(0)
1 ppm= _
mg/m3
VapourPressure
at 20 °C (kPa)
Henn/s Law
Constant
(atm 1m3/mol)
naphthalene 128.16 5.238 0.01 a 4.6 x 10-4
fluoranthene 202.26 8.267 1.3 x 10-3 6.5 x 10-6
chrysene 228.28 9.331 8.4 x 10-9b 1.05 x 10-6
anthracene 178.22 7.285 2.27 x 10-613 8.6 x 10-5
dibenz(a,h)anthracene 278.36 11.378 1.3 x io-9 7.3 x 10-8
dibenz(a,c)anthracene 278.36 11.378


benz(a)anthracene 228.30 9.332 2.9 x 10-7 1 x 10.6
phenanthrene 178.24 7.285 1.3 x 10-4b 2.26 x 10-4
1-methylphenanthrene 192.27 7.859


benzo(b)fluoranthene 252.32 10.313 6.7 x 10-6 1.22 x 10'5
benzo(j)fluoranthene 252.32 10.313 2 x 10-7b 7.39 x 10-7
benzo(k)fluoranthene 252.32 10.313 6.7 x 10-7 3.87 x 10-5
pyrene 202.26 8.267 3.3 x 105b 5.1 x 10-6
benzo(a)pyrene 252.32 10.313 7.5 x 108
 a 4.9 x 10-7
benzo(e)pyrene 252.32 10.313


cyclopenta(c,d)pyrene 226.28 9.249


indeno(1,2,3-cd) pyrene 276.34 11.295 -1.3 x 10-9 6.95 x 10-6
perylene 252.32 10.313


benzo(ghi)perylene 276.34 11.295 1.3 x 10-9 1.44 x 10-7
fluorene 166.23 6.795


0.6-7.1 x 10-4
acenaphthylene 152.20 6.221 3.8 x 10-3 1.45 x 10-3
acenaphtene 154.22 6.304 6.0 x 104


coronene 300.36 12.277


a temperature not specified
b calculated at 25 °C
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NAPHTHALENE
Two year inhalation studies showed no evidence of carcinogenicity of naphthalene following
exposure of male mice (strain B6C3F1) to 10 or 30 ppm (NTP, 1992). Carcinogenicity was
evident in female mice of the same strain chronically exposed to 30 ppm (157 mg/rn3).
Carcinogenicity was based on an increased incidence of pulmonary alveolar/bronchiolar
adenomas. However the incidence of tumours in the mice exposed to 10 ppm (52 mg/rn3)was
lowerthan that of the controls. Itwas concluded that there was some evidence of naphthalene
carcinogenicity in female mice.
US EPA, (1990) reported no carcinogenic activity in female mice (strain NJ) following exposure
to 10 or 30 ppm (52 or 157 mg/rn3)naphthalene. Exposure periods were 6h/day, 5d/week for
6 months.
Adkins, et aL, (1986) exposed mice to 30 ppm (157 mg/rn3)naphthalene for 6h/day, 5d/week
for 6 months. No effect on the number of tumour-bearing mice was reported, although an
increase in the number of tumours per tumour bearing mouse was reported.
US EPA Classification of human carcinogenicity: D "not classifiable as to human
carcinogenicity". This is due to the lack of human data and inadequate data from animal
bioassays.
IARC classification: 3
Additional studies on the carcinogenicity of naphthalene (non-inhalation exposures) are listed
in US Department of Health & Human Services, (1993).
FLUORANTHENE
US EPA Classification of human carcinogenicity: D "not classifiable as to human
carcinogenicity". This is due to the lack of human data and inadequate data from animal
bioassays.
No information available for inhalation exposure.
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CHRYSENE
Wenzel-Hartung, et aL, (1990) reported a dose-related increase in the incidence of squamous
cell carcinomas in rats given an intra-pulmonary implantof 1 or 3 mg chrysene. Chrysene has
been implicated as an etiological determinant of chemical carcinogenesis. Chrysene has been
reported to induce aryl hydrocarbon hydroxylase in cultured human lymphocytes (Snodgrass,
1979). Aryl hydrocarbon hydroxylase was not induced in mitogen-activated cultured human
lymphocytes from healthy donors (Gurtoo, 1979).
Classified by US EPA as B2, "probable human carcinogen" (classifiction was based on non-
inhalation studies).
Details of other carcinogenicity studies (non-inhalation exposure routes) are reported in (US
Department of Health & Human Services, 1990d).
ANTHRACENE
US EPA Classification of human carcinogenicity: D "not classifiable as to human
carcinogenicity" .This is due to the lack of human data and inadequate data from animal
bioassays.
Details of carcinogenicity studies are available, but not from inhalation exposure.
DIBENZ(a,h)ANTHRACENE
Wenzel-Hartung, et al., (1990) reported over 50% of rats given an intrapulmonary implant of
0.1 mg dibenz(a,h)anthracene developed squamous cell carcinomas (one rat developed a
begnign squamous cell tumour). Only one dose of dibenz(a,h)anthracene was used in this
study.
A slight increase in repiratory tract tumours was reported in male hamsters given a weekly
dose of 0.25 mg for 24 to 30 weeks (Sellakumar& Shubik, 1974). Dibenz(a,h)anthracene was
reported to be a weak to moderate respiratory carcinogen.
Yanysheva & Balenko, (1966) reported a dose-related increase in the number of rats
developing squamous cell carcinomas within 30 months of intratracheal instillation of 0.5, 2,
10 or 20 mg dibenz(a,h)anthracene. The lowest dose which induced tumours was 2 mg.
US EPA Classification of human carcinogenicity: 82 "probable human carcinogen". There are
no human data, but sufficient data from animal bioassays (none listed are from inhalation
exposure).
Detailsof othercarcinogenicitystudies (non-inhalationexposures) are listed in (US Department
of Health & Human Services, 1990e).
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DIBENZ(a,c)ANTHRACENE (BENZO(b)TRIPHENYLENE)
IARCclassification: 28 "possibly carcinogenic to humans" Classification was based on limited
animal evidence, and no adequate human data. No inhalation studies listed.
BENZ(a)ANTHRACENE
US EPA Classification of human carcinogenicity: B2 "probable human carcinogen". There are
no human data, but sufficient data from animal bioassays (none listed are from inhalation
exposure).
IARCclassification: 2A, "probably carcinogenic to humans". There are sufficient animal data,
no human data
Details of other carcinogenicity studies (non-inhalation exposure) are reported in US
Department of Health & Human Services, (1990a).
PHENANTHRENE
Wenzel-Hartung, et aL, (1990) reported a squamous cell carcinoma in a single rat given an
intrapulmonary implant of 10 mg phenanthrene. No carcinomas were reported in the other rats
in this dose group, or in rats given 1 or 3 mg implants. The authors suggested that the single
carcinoma reported may have been spontaneous since there was no increase in the incidence
of squamous cell metaplasias (pre-neoplastic lesions) in any of the exposure groups with
reference to the vehicle or untreated controls.
US EPA Classification of human carcinogenicity: D "not classifiable as to human
carcinogenicity" .This is due to the lack of human data and inadequate data from animal
bioassays. (No data for inhalation exposure listed).
IARC classification: 3 "not classifiable as to carcinogenicity to humans", due to lack of human
data and inadequate animal data.
1-METHYLPHENANTHRENE
IARC classification: 3, "not classifiable as to its carcinogenicity to humans". Due to lack
of human data, and inadequate animal data.
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BENZO(b)FLUORANTHENE
Deutsch-Wenzel, et aL, (1983b) reported a dose-related increase in the number of rats with
epidermoidcarcinomas or pleomorphicsarcomas following intra-tracheal injection of 0.3 or 1.0
mg (0.4, 1.2 or 4.1 mg/kg). Rats given 0.1 mg did not develop tumours. Benzo(b)fluoranthene
was classified as a moderately active respiratory carcinogen.
Classification of human carcinogenicity: B2 "probable human carcinogen". There is no human
data, but sufficient animal data.
IARC classification: 2B "possibly carcinogenic to humans. No human data is available, but
there are sufficient data on the carcinogenicity in animals.
Details of other carcinogenicity studies (non-inhalation exposure) are reported in US
Department of Health & Human Services, (1990c).
Unlike other PAHs benzo(b)fluoranthene does not form bay region diol epoxides, but it
does form reactive metabolites which may form DNA adducts.
BENZOWFLUORANTHENE
Deutsch-Wenzel,et al., 1983b) reported a dose-related increase in epidermoid carcinomas in
rats given a pulmonary implant of 0.2, 1.0 or 5.0 mg. The dose 1.0 mg (25 mg/kg) was
reported to be carcinogenic by RTECS criteria.
Grimmer, et aL, 1982) reported that 5 mg/kg benzo(j)fluoranthene applied as a pulmonary
implant to rats gave an equivocal tumourogenic response, based on RTECS criteria.
IARC classification: 2B, "possibly carcinogenic to humans". There are no human data, but
sufficient animal data.
BENZO(k)FLUORANTHENE
Deutsch-Wenzel, et al., (1983b) reported a dose-related increase in epidermoid carcinomas
in rats given a pulmonary implant of 0.83 or 4.15 mg. No carcinomas were reported in rats
given a 0.16 mg implant.
Grimmer, et al., (1982) reported that 5 mg/kg benzo(k)fluoranthene applied as a pulmonary
implant to rats gave an equivocal tumourogenic response, based on RTECS criteria.
US EPA Classification of human carcinogenicity: B2, "probable human carcinogen". There is
no human data, but sufficient animal data.
IARC classification: 2B, "possibly carcinogenic to humans". There are no human data, but
sufficient animal data.
Relative potency of PAHs - 1st draft to PD (HMIP) / 4 February 1994 8
PYRENE
US EPA Classificaton of human carcinogenicity: D, "not classifiable as to human
carcinogenicity" . Classification based on no human data, and inadequate animal data.
IARC cassification: 3, "not classifiable as to its carcinogenicity to humans". There are no
human data, and inadequate animal data.
BENZO(a)PYRENE
Increased lung neoplasms (10 fold) reported in rats and mice exposed to 50 to 90 pg/m3for
16h/day,5 days/week for 22 months (Heinrich, et aL, 1986). Anon (1982) reported tumours in
0 miceexposed to benzo(a)pyrene at 200 ng/m3 for 6 hours/ day for 13 weeks. Benzo(a)pyrenewas classified as an equivocal tumourogenic agent. A dose-related increased incidince of both
respiratory tract and upper gastro-intestinal tract tumours was reported in Golden hamsters
exposed to benzo(a)pyrene at 2.2, 9.5 or 46.5 mg/m3for 4 hours per day x 96 weeks (Thyssen
0 et al., 1981).
Deutsch-Wenzel, et al., (1983b) reported a dose-related increase in epidermoid carcinomas
in rats given a pulmonary implant of 0.1, 0.3 or 1.0 mg.
Grimmer, et aL, (1984) reported 150 pg/kg benzo(a)pyrene implanted in rat lungs was
carcinogenic by RTECS criteria. Tumours were noted at the site of application.
Deutsch-Wenzel,et aL, (1983a) reported 500 pg/kg benzo(a)pyrene implanted in rat lungs was
carcinogenic by RTECS criteria.
A pulmonary implant of 200 mg/kg benzo(a)pyrene was reported to be carcinogenic to mice,
based on RTECS criteria (Anon, 1979a).
Intra-tracheal administration of 200 mg/kg benzo(a)pyrene at 10 week intervals was reported
to be neoplastic, according to RTECS criteria (Anon, 1979b).
Benzo(a)pyrene is classified as B2, probable human carcinogen. There are no data
specifically linking benzo(a)pyrene to human carcinogenicity, but much data is available on
carcinogenicity to animals following exposure to benzo(a)pyrene via a variety of routes,
including inhalation. Benzo(a)pyrene has been used as a positive control in carcinogenicity
assays of other chemicals. Such studies tend to use single dose of benzo(a)pyrene, and are
therefore of limited use in establishing a dose-response relationship.
IARC classification: 2A "probably carcinogenic to humans".
US EPA classification: B2 "probably carcinogenic to humans"
Details of other carcinogenicity studies (non-inhalationexposure) are listed in US Department
of Health & Human Services, (1990b).
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BENZO(e)PYRENE
Deutsch-Wenzel, et al., (1983b) did not report a dose-related increase in carcinogenicity
following application of benzo(e)pyrene as a pulmonary implant. The highest dose tested, 5.0
mg produced only one rat with a epidermoid carcinoma. One rat in the 1.0 mg dose group
developed a pleomorphic sarcoma.
IARC classification:3, "not classifiable as to its carcinogenicity to humans". There are no
human data, and inadequate animal data.
Other studies listed, but not for inhalation exposure.
CYCLOPENTA(c,d)PYRENE
IARC classification: 3, "not classifiable as to its carcinogenicity to humans". There are limited
animal data, and no adequate human data
INDEN0(1,2,3-CD)PYRENE
Deutsch-Wenzel, et al., (1983b) reported a dose-related increase in the number of rats
developing epidermoid carcinomas. The rats were given pulmonary implants containing 0.16,
0.83 or4.15 mg indeno(1,2,3-CD)pyrene (0.65, 3.4 and 17 mg/kg, respectively). Tumours were
reported in rats from each dose group. The 4.15 mg dose was classified as carcinogenic, with
reference to RTECS criteria.
Grimmer,et al., (1982) reported that a pulmonary implant of 5 mg/kg indeno(1,2,3-CD)pyrene
hgave an equivocal tumourogenic response, based on RTECS criteria, in rats.
US EPA Classification B2, "probable human carcinogen". There are no human data, but
sufficient animal data, including lung implants. No inhalation studies listed.
IARC classification: 2B, "possiby carcinogenic to humans". There are no human data, but
sufficient animal data.
PERYLENE
IARC classification: 3, "not classifiable as to its carcinogenicity to humans". There are no
human data, and inadequate animal data.
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BENZO(ghi)PERYLENE
Benzo(ghi)perylene implants of 0.16, 0.83, or 4.15mg (0.65, 3.4 or 17 mg/kg, respectively) in
rat lungs showed a weak (non-significant) tumourigeniceffect (Deutsch-Wenzel, et al., 1983b).
The authors reported that a dose-response relationshipfor this individual PAH compound was
not significant. The small number of tumours produced may have been caused by impurities
in the benzo(g,h,i)perylene implant.
IAFICclassification: 3, "not classsifiable as to its carcinogenicity to humans". There are no
human data and inadequate animal data.
FLUORENE
US EPA classification: D, "not classifiable as to its human carcinogenicity". This is based on
no human data, and inadequate data from bioassays.
IARC classification: 3, "not classifiable as to its carcinogenicity to humans". There are no
human data, and inadequate animal data.
No studies with inhalation exposure listed.
ACENAPHTHYLENE
US EPA classification: D, "not classifiable as to its carcinogenicity to humans". This is based
on no human data, and inadequate animal data.
No inhalation studies listed.
ACENAPHTHENE
Reshetyuk, (1970) reported no malignant growths in rats exposed to acenaphthene at 12 ±1.5
mg/m3for four hours per day, six days per week for eight months.
CORONENE
IARC classification: 3 "not classifiable as to its carcinogenicity to humans". There is a lack of
adequate human data, and inadequate evidence of carcinogenicity to animals.
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Table 3 Carcinogenicity classifications of PAH compounds
Name . Gerrie, et al., (1991) IARC
classification
US EPA
Classification
Eisler, (1987)
naphthalene


3 D non carcinogenic
fluoranthene tumourigenic in new born
mouse lung bioassay. No
activity on mouse skin or
SC. illf


D non carcinogenic
chrysene inactive as complete
carcinogen, although a
weak initiator-promoter
(IARC, 1983)


B2 weak carcinogen
anthracene


D non carcinogenic
dibenz(a,h)anthracene moderate carcinogen,
activity lies between BA
and BaP.


B2 strong
carcinogen
dibenz(a,c)anthracene inactive, or weak
carcinogen in mouse skin,
but shows significant
tumour-initiating activity
with TPA promotion.
26


weak carcinogen
benz(a)anthracene weakly carcinogenic
compared to BaP in most
test systems
2A B2 weak carcinogen
/ co-carcinogen -
tumourogen
phenanthrene


3 D non-carcinogen
1-methylphenanthrene


3


benzo(b)fluoranthene


26 B2 carcinogen
benzo(j)fluoranthene weak tumour-initiating
agent. Less active than
benzo(b)fluoranthene
26


carcinogen
benzo(k)fluoranthene Inactive as complete
carcinogen on mouse
skin, or lung or liver in
newborn mice. Acts as
tumour initiator on mouse
skin and induces
fibrosarcomas following
sc inj to mice.
2B 62 non-carcinogen
pyrene ' generally considered non-
carcinogenic
3 D non-carcinogen
benzo(a)pyrene potent carcinogen, used
as reference for other
PAHs.
2A 62 strong
carcinogen
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Name Gerde, et al., (1991) IARC
classification
US EPA
Classification
Eisler, (1987)
benzo(e)pyrene Inactive as a complete
carcinogen, but a weak
tumour initiator with TPA
promotion (IARC, 1983)
3


non carcinogen
cyclopenta(c,d)pyrene
-
Much less active than
BaP as a cpmplete
carcinogen or tumour
initiator. Potent
tumourigen in the
newborn mouse assay.



indeno(1,2,3-cd)pyrene Lower activity than BaP
as a complete carcinogen
on mouse skin.
2B B2 weak carcinogen
/ co-carcinogen /
tumourogen
perylene No activity as a complete
carcinogen or tumour
initiator
3


benzo(ghi)perylene Non-carcinogenic (IARC,
1983)
3 2 (Limited) non-carcinogenic
fluorene No tumours in rats or
mice (IARC, 1983)
3 D non-carcinogenic
acenaphthylene


D


acenaphtene



coronene


3


Relative potency of PAlis - 1st draft to PD (11M1P)/ 4 February 1994 13
Table 4: Relative Potency (RP) of PAH compounds reported in the literature, with reference to benzo(a)pyrene.
Name RP (1) RP (2) RP (3) RP (4) RP (5) RP (6) RP (7)
naphthalene 0.001


o



fluoranthene 0.001


0



chrysene 0.001


1


0.03


anthracene 0.01


0 0.19


dibenz(a,h)anthracene 5 1.1 0.69 1


1.908 0.59
dibenz(a,c)anthracene





benz(a)anthracene 0.1 0.145 0.013 1


0.16
phenanthrene 0.001


0


0.001


1-methylphenanthrene





benzo(b)fluoranthene 0.1 0.140 0.08 1 0.11


0.024
benzoWfluoranthene



0.03


0.08
benzo(k)fluoranthene 0.1 0.066 0.004 1 0.03


pyrene 0.001 0.081


0



benzo(a)pyrene 1 1 1 1 1.00 1


benzo(e)pyrene



0.003


cyclopenta(c,d)pyrene





indeno(1,2,3-cd)
pyrene
0.1 0.232 0.017 1 0.08


0.006
perylene





benzo(ghi)perylene 0.01 0.022


0 0.01


fluorene 0.001


0



acenaphthylene 0.001


0



acenaphtene 0.001


0



coronene





(Nisbet & LaGoy, 1992)
Clement (1988) cited in (Nisbet & LaGoy, 1992)
Chu & Chen (1984) cited in (Nisbet & LaGoy, 1992)
US EPA (1984) cited in (Nisbet & LaGoy, 1992)
(Deutsch-Wenzel,et al., 1983b)
(Wenzel-Hartung,et al., 1990)
(Rugen, et at, 1989)
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Table 5 RALs calculated from highest reported RP
Name Relative Potency based
on highest reported
value
RAL
pg/rn2
naphthalene 0.001 1 x 10-2
fluoranthene 0.001 1 x 10-2
chrysene 0.03 3 x 104
anthracene 0.32 3 x 10
dibenz(a,h)anthracene 5 2 x 10'6
dibenz(a,c)anthracene 0.1 1 x 104
benz(a)anthracene 0.1 1 x 10-4
phenanthrene 0.001 1 x 10-2
1-methylphenanthrene 0.001 1 x 10-2
benzo(b)fluoranthene 0.1 1 x 104
benzo(j)fluoranthene 0.01 1 x 104
benzo(k)fluoranthene 0.1 1 x 1u4 .
pyrene 0.081 1 x 10-4
benzo(a)pyrene 1.0 1 x 10
benzo(e)pyrene 0.003 3 x 104
cyclopenta(c,d)pyrene 0.001 1 x 10'2
indeno(1,2,3-cd)pyrene 0.232 4 x 10's
perylene 0.001 1 x 10'2
benzo(ghi)perylene 0.022 4 x 10'4
fluorene 0.001 1x 10'2
acenaphthylene 0.001 1 x 104
acenaphtene 0.001 1 x 10.2
coronene 0.001 1 x 102
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Table 6 RALs calculated from RP using solely pulmonaryexposure data (Deutsch-Wenzel, et al., 1983b;
Wenzel-Hartung, et al., 1990)
Name Relative Potency based
on highest reported
value
RAL
pg/rn3
naphthalene


fluoranfhene


chrysene 0.03 3 x 10-4
anthracene 0.19 5 x 105
dibenz(a,h)anthracene 1.908 5 x 10-6
dibenz(a,c)anthracene


benz(a)anthracene


phenanthrene 0.001 1 x 10-2
1-methylphenanthrene


benzo(b)fluoranthene 0.11 1 x 10-4
benzo(j)fluoranthene 0.03 3 x 10-4
benzo(k)fluoranthene 0.03 3 x 10-4
pyrene


benzo(a)pyrene 1.00 1 x 10-5
benzo(e)pyrene 0.003 3 x 10.3
cyclopenta(c,d)pyrene


indeno(1,2,3-cd)pyrene 0.08 1 x 10-4
perylene


benzo(ghi)perylene 0.01 1 x 10-3
fluorene


acenaphthylene


acenaphtene


coronene
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Table 7: Percentage contribution of different PAHs of a total PAH in typical air sample, as in TOMPS
programme
Name Percentage contribution of different PAHs to a
typical total PAH (%)
naphthalene 0.001
fluoranthene 7.4
chrysene 7
anthracene 25.7
dibenz(a,h)anthracene 0.1
dibenz(a,c)anthracene 0.1
benz(a)anthracene 12.8
phenanthrene 46.2
1-methylphenanthrene 0.1
benzo(b)fluoranthene 15.8
benzo(j)fluoranthene 0.001
benzo(k)fluoranthene 6.1
pyrene 6.9
benzo(a)pyrene 0.1
benzo(e)pyrene 0.001
cyclopenta(c,d)pyrene 0.001
indeno(1,2,3-cd)pyrene 0.001
perylene 0.001
benzo(ghi)perylene 3.0
fluorene 17.6
acenaphthylene 5.9
acenaphtene 0.1
coronene 0.1
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DISCUSSION
There is a paucity of data available on the carcinogenicity of individual PAH compounds to
experimental animals following inhalation exposure. With the exception of benz(a)pyrene,
naphthalene, and acenaphthene, the potential carcinogenic activity of individual PAH
compounds has not been reported following inhalation exposure. Details on the carcinogenic
activityof some these compounds are available from bioassasys with non-inhalation exposure
routes, including pulmonary implants. Care must be taken when interpreting these studies
since this route is not directly relevant to inhalation exposure. However this route was used by
Wenzel-Hartung, et al., (1990) and Deutsch-Wenzel, et al., (1983b) to determine the relative
potencyof individual PAHcompounds, with referenceto benz(a)pyrene. The toxic equivalence
factors (TEFs) calculated in these studies are listed in Table 4. Table 4 also lists TEFs which
have been calculated in other studies using data from all exposure routes including pulmonary
implant, dermal, subcutaneous and in vitro administrations
The TEFs used to calculate the RALs are listed in Table 4. The RALs listed in Table 6 are
based upon the worst case scenario, i.e. the highest TEF value, without reference to the route
of exposure. The RALs listed in Table 7 are based upon the two pulmonary implant studies
(Deutsch-Wenzel, et al., 1983b; Wenzel-Hartung, et al., 1990). TEFs were assigned to
compounds which did not have a value reported in the literature according to their
carcinogenicity classifications, with reference to the carcinogenicity classifications of
compounds for which TEFs had been reported.
Nisbet & LaGoy, (1992) reported that the use of TEFs requires several assumptions. These
are as follows:
1 A reasonably well-characterised compound can be selected to serve as a
reference compound for other compounds in the group.
2 The toxic effects of all members of the group are qualitativley similar to those of
the reference compound, and may therefore be characterised quantitatively by
means of a relative potency or TEF.
3 TEFs for diferent toxic endpoints are similar, so that limited information on reative
toxic potencies in one or a few assay systems can be used to assign TEFS to
single compounds or subclasses for other end points.
4 The toxic effects of different compounds of the mixtures are additive.
For PAHs, assumption one is satisfied by use of benzo(a)pyrene as the reference compound.
Benzo(a)pyrene is one of the most potent carcinogens, and its carcinogenicity and related
effects in several different assay systems have been well studied. Assumption two is satisfied
since the primary concern for risk assessment of PAHs is carcinogenicity. Many of the
individual PAH compounds have been tested for carcinogenicity for at least one route of
exposure, and subsequently classified by IARC or the US EPA. Assumption three is not
relevant to the scope of this report, which is aimed at carcinogenicity following inhalation
exposure. However it should be considered when examining TEFs calculated from other
studies, although those listed are all based on carcinogenicity. (Nisbet & LaGoy, 1992) cited
studieswhich they claimdemonstrated similarities in relative potencies for different end points.
Assumption four is satisfied by data cited in Nisbet & LaGoy, (1992). This data was derived
from studies where mice were exposed to individual PAH compounds and mixtures of PAH
compounds via dermal or sub-cutaneous exposure. The data provided demonstrated that the
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carcinogenicity of individual PAH compounds is additive. This is an important consideration,
as it allows a RAL to be calculated for Total PAH, based on the existing RAL for
benzo(a)pyrene.
Tables 5 and 6 demonstrate that the RALs calculated for four of the seven individual PAH
compounds administered via pulmonary implant (Deutsch-Wenzel, et al., 1983b;
Wenzel:Hartung, et al., 1990) do not vary by more than an order of magnitude between relative
potencies calculated by other studies. This suggests that the carcinogenicity of PAH
compounds is not affected by the route of exposure,
The data in table 7 can be used to calculate an RAL for total PAH. The sum of the
percentagesgiven in this table is greater than 100%,so the the proportions need to be altered
accordingly, to allow the RAL to be calculated. (Peter Douben to supply data).
The TEFs previously published (Deutsch-Wenzel, et al., 1983b; Rugen, et al., 1989;
Wenzel-Hartung, et al., 1990) did not appear to take into account the molecular weight of the
individual PAH compounds. The method of calculation used iii these papers was not reported,
other than that probit analysis was used. Calculationsof TEFs should take into account molar
ratios, since it is indicative of the number of molecules present which can form DNA adducts;
the inducer of the carcinogenic effects.
There are limitations in the calculation of a RAL for total PAHs based on the sum of the RALs
of individual PAH compounds. A RAL for Total PAH is likely to be of greater relevance to
environmental exposure since exposure to single PAH compounds is unlikely. However there
are limitations in the studies involovingexposure to individual PAH compounds, as some PAHs
have been classified as having co-carcinogenicity (Eisler, 1987). This means that although no
carcinogenicity was reported following exposure to the compound on its own, the compound
may contribute to carcinogenicity in a PAH mixture. The assumption that the toxic effect of
individual PAH compounds are additive underestimates this risk.
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ANNEX 1 CLASSIFICATION OF CARCINOGENS (IARC / US EPA)
The classification scheme used by the International Agency for Research on Cancer (IARC) consists
of five categories:
Group Description Basis of classification
1 carcinogenic to humans sufficient human evidence
2A. probably carcinogenic to
humans
limited human evidence and
sufficient animal evidence
26 possibly carcinogenic to
humans
limited human evidence or
sufficient animal evidence
3 not classifiable as to
carcinogenicity to humans
agents which do not fit into
any other group
4 probably not carcinogenic to
humans
lack of carcinogenicity in
humans and animals
The following definitions are used in the IARC carcinogenicity classification:
sufficient evidence
limited evidence
inadequate evidence
a positive causal relationshipbetween exposure to the agent and cancer
has been established in which chance, bias and confounding factors
could be ruled out with reasonable confidence. Experimental evidence
may demonstrate an increased incidence of malignant neoplasms (or a
combination of benign and malignant neoplasms) in either a) two or more
species of animal, b) two or more independant studies on one species,
or c) in exceptional cases, one species with a high incidence.
a credible positive causal relationshiphas been established, but chance,
bias and confounding factors could not be ruled out with resonable
confidence. Experimental data suggest carcinogenicity but definite
classification is not possible because of one or more of the following
factors: a) single experimentavailable, b) there are unresolved questions
regarding experimental design or interpretation, c) only benign tumours
were reported.
available studies of insufficientquality, consistency or statistical power to
permit a conclusion to be reached. Experimental data show qualitative or
quantitative limitations
evidence suggesting lack several adequate studies, covering the full range of doses to which
of carcinogenicity humans are known to be exposed, fail to show a positive association
between exposure to the agent, and any studied cancer at any observed
level of exposure. The possibility of a very small risk at the levels of
exposure studied in not excluded. Experimental data should be avaialble
for at least two species. This conclusion is neccessarily limited to the
species, tumour sites and doses of exposure studied.
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The classification scheme used by the US Environmental Protection Agency (US EPA) is similar to the
one used by IARC, although it consists of six categories. These are as follows:
Group


description
A


human carcinogen
B1


probably carcinogenic to humans (limited
human evidence)
B2


probably carcinogenic to humans (no or
inadequate human evidence and sufficient
animal evidence)
C


possible human carcinogen
D


not classifiable as to carcinogenicity to
humans
E • non-carcinogenic to humans.
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